IRCT20090117001556N119招募中3 期
Evaluation of the efficacy of gemfibrozil as an adjunct therapy in improving the symptoms of major depressive disorder; A double- blind, placebo-controlled trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Presence of Major Depressive Disorder based on DSM-5 criteria
- •Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22
- •Age between 18 to 60 years
排除标准
- •Presence of psychosis
- •Substanse use disorder except for nicotine and caffeine
- •IQ lower than 70
- •Any other mental disorder
- •Any significant neurologic or medical disease(advanced renal disease, CKD, hepatic disease, cardiovascular disease)
- •history of cholelithiasis
- •Receiving Warfarin
- •Recieving Insulin
- •Receiving statins
- •Receiving niacin
研究者
相似试验
招募中
3 期
Efficacy of Gemfibrozil as an adjust therapy in obsessive compulsive disorder, a randomized clinical trial with medication controlObsessives-Compulsive disorder.Obsessive-compulsive personality disorderF60.5IRCT20230211057389N1Karaj University of Medical Sciences40
已完成
1 期
To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656Type 2 Diabetes MellitusNCT01083212AstraZeneca19
已完成
1 期
Drug-Drug Interaction Study of Mitiglinide and GemfibrozilType 2 Diabetes MellitusNCT00566865Elixir Pharmaceuticals14
尚未招募
不适用
Study of absorption and elimination rate of Gemfibrozil 300-mg capsule in comparison with gemfibrozil brand capsule (Lopid®).Bioequivalence study.IRCT20200407046981N28Daana pharmaceutical company24
已完成
不适用
effect of Gemfibrozil for treatment of cigarettenicotine dependence.Mental and behavioural disorders due to use of tobaccoIRCT2017101732057N3Vice chancellor for research of Kashan University of Medical Sciences and Health Services76